Acute inflammation with induction of anaphylatoxin C5a and terminal complement complex C5b-9 associated with multiple intra-articular injections of hylan G-F 20: a case report  by Dragomir, C.L. et al.
Osteoarthritis and Cartilage 20 (2012) 791e795Brief Report
Acute inﬂammation with induction of anaphylatoxin C5a and terminal
complement complex C5b-9 associated with multiple intra-articular injections
of hylan G-F 20: a case report
C.L. Dragomir y*, J.L. Scott z, G. Perino x, R. Adler k, S. Fealy{, M.B. Goldring y
y Tissue Engineering, Repair and Regeneration Program, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
zAutoimmunity and Inﬂammation Program, Hospital for Special Surgery, USA
xDepartment of Pathology and Laboratory Medicine, Hospital for Special Surgery, USA
kDepartment of Radiology and Imaging, Hospital for Special Surgery, USA
{Department of Sports Medicine and Shoulder Service, Hospital for Special Surgery, USAa r t i c l e i n f o
Article history:
Received 29 November 2011
Accepted 26 March 2012
Keywords:
Acute local inﬂammatory reaction to hylan
G-F 20
Synovial ﬂuid anaphylaxis
Terminal complement complex* Address correspondence and reprint requests to
Engineering, Repair and Regeneration Program, Hosp
East 70th Street, New York, NY 10021, USA. Tel: 1-21
2373.
E-mail addresses: dragomirc@hss.edu (C.L. Dragom
perinog@hss.edu (G. Perino), adlerr@hss.edu (R. Adle
goldringm@hss.edu (M.B. Goldring).
1063-4584/$ e see front matter  2012 Osteoarthriti
doi:10.1016/j.joca.2012.03.020s u m m a r y
Objective: The purpose of this case report was to investigate local immune mechanisms present during an
acute inﬂammatory ﬂare initiated by viscosupplementation with hylan G-F 20 in a patient with osteo-
arthritis (OA) and past meniscectomy.
Experimental design: A patient with a history of bilateral OA and partial left knee meniscectomy, who had
received three injections of hylan G-F 20, was diagnosed with an acute ﬂare reaction in the left knee. Her
chart was evaluated for clinical, radiological, and laboratory ﬁndings and for clinical follow-up. Histo-
pathological synovial examination and real-time polymerase chain reaction (RT-PCR) for genes with
major roles in local inﬂammation and enzyme-linked immunosorbent assays (ELISAs) for markers of
complement activation and cytokines were performed. To study the impact of the inﬂammatory and
immune features we compared the case patient with groups of three representative OA and three
rheumatoid arthritis (RA) patients.
Results: The patient exhibited evidence of highly increased acute phase reactant C-reactive protein (CRP)
in the blood. The pathological examination of the synovial membrane identiﬁed abundant ﬁbrinous
exudate with numerous particles of hyaluronan surrounded by a dense inﬁltrate of neutrophils and
eosinophils. The synovium had moderate hypertrophy and sclerosis as well as an inﬂammatory inﬁltrate
predominantly composed of T lymphocytes and macrophages with scattered perivascular eosinophils
and neutrophils. Immunoperoxidase staining identiﬁed numerous deposits of C5b-9 in the ﬁbrinous
exudates and the synovial membrane of the patient. Similar ﬁndings were observed in the RA patients,
whereas deposits were rare in OA synovial samples. In addition, both anaphylatoxin C5a and the terminal
complement complex C5b-9 were present at high levels, comparable to those in RA patients. The levels of
mRNA for interleukin-1 beta (IL-1b), IL-6, and the neutrophil marker myeloperoxidase (MPO) were
markedly increased compared to those in the RA and OA patients.
Conclusions: This present study is indicative of a pseudo-septic acute inﬂammatory reaction in response
to local accumulation of hylan G-F 20 with the activation of complement and local invasion of pro-
inﬂammatory cells.
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Hylan G-F 20 (Genzyme Biosurgery, Cambridge, MA) is a safe
and generally well-tolerated viscosupplementation for intra-
articular injections in patients with symptomatic osteoarthritis
(OA)1,2 as well as after arthroscopic meniscectomy3. Severe local
ﬂares have been described as rare reactions in patients with bilat-
eral OA and a history of unilateral meniscectomy4. While distinctive
inﬂammatory ﬂares were previously described, a clear mechanismublished by Elsevier Ltd. All rights reserved.
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G-F 20 gains immunogenicity by chemical cross-linked processing
that enables it to persist longer when injected in the knee6. In
addition, in patients who underwent meniscectomy, cytokine-
driven synovial inﬂammation occurs more frequently than in
patients with established knee OA7. In these patients speciﬁcally,
the combination of the two may be one of the possible risk factors
involved in the pathogenesis of the ﬂare-ups.
In our case report, we provide histological and immune-
biochemical evidence to suggest that the local ﬂare is possibly an
immune mechanism with features of a reactive-like arthritis with
complement activation and production of inﬂammatory cytokines
without ignoring other potentially distinctive mechanisms. To our
knowledge, this is the ﬁrst description of the possible local
involvement of the complement pathway in a synovial ﬂuid and
tissue immune reaction to hylan G-F 20.
Methods, results and discussion
We present the case of a 55-year-old woman with bilateral OA,
who had undergone left knee meniscectomy 9 years previously and
received inthe last year two5 ml treatmentswithhylanG-F20 inboth
kneesatourhospital. The radiographdiagnoseda severegrade4OA in
the left knee without evidence of chondrocalcinosis in either knee.
Approximately 12 h after the third injection in both knees the
patient presented with local massive swelling accompanied by
severepain limited to the left knee joint. Systemic reactionswerenot
described. Decompression by ultrasound-guided aspiration of the
left knee joint was performed in the next 12 h yielding 65 ml of
yellowish synovialﬂuidﬁlledwith inﬂammatory cells (WBC33,950/
mm3, RBC 1500/mm3, neutrophils 60%, eosinophils 18%, monocytes
19% and lymphocytes 3%). The swelling and pain returned rapidly to
the previous state and an emergency arthroscopic irrigation and
debridement were performed the following day. Synovial ﬂuid and
tissue were collected for further processing. The blood reports
indicatedacutephase reactantswith slightlyelevatedESRat33 mm/
h (Westergren method, normal values¼ 0e27 mm/h) and high C-
reactive protein (CRP) at 6.4 mg/dl (normal values range from 0 to
1 mg/dl).Microscopic examination of freshly prepared synovial ﬂuid
for crystal deposits, Gram’s stain, and cultures of the synovial ﬂuid
were all negative. The treatment included oral ciproﬂoxacin for 7
days andnon-steroidal anti-inﬂammatorydrugs, analgesics, andrest.
During the arthroscopic debridement, synovial exudate and
tissue were obtained and placed in 15 ml of Dulbecco’s Modiﬁed
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) for explant culture at 37C. After a week, the primary synovial
culture revealed a mixed population with 35% representing
macrophages containing microvesicles with hylan G-F 20 [50
magniﬁcation; Fig. 1(A (i)) and 200magniﬁcation; Fig. 1(A (ii))]. In
addition, 5-mm thin formalin-ﬁxed parafﬁn embedded sections of
exudate and tissue obtained during arthroscopy were stained with
hematoxylin and eosin (H&E; SigmaeAldrich, St. Louis, MO), and
antibodies against CD3/CD5 for T-cells, CD20 for B-cells, CD117 for
mast cells, and CD68 for macrophages (all from Esoterix Genetic
Laboratories, NY, NY, USA), as well as anti-C5b-9 (Antibody Shop,
Denmark). Images viewed by ImageJ served to count the cells and
evaluate the percentage differences between primary and immune
cells, as described by Girish et al.8. The histological pattern of the
acute reaction to hylan G-F 20 described previously is of a peculiar
granulomatous reaction, with palisading macrophages around
hyaluronan particles and multinucleated giant cells9. In contrast, as
seen in Fig. 1(B (i) and (ii)), the ﬁbrinous exudate from the case
patient joint contained numerous fragments of non-birefringent
amorphous material (hylan G-F 20) surrounded by a thick cuff of
neutrophils and eosinophils, forming inﬂammatory pseudo-abscesses. This result was in marked contrast to the relatively
free surface of the synovial membrane [Fig. 1(B (iii))]. Interestingly
in our case, the new acute antigenic property was conﬁrmed by the
focal presence of old hylan G-F 20 particles in the synovium with
a typical chronic macrophagic reaction and the attraction of acute
inﬂammatory cells [Fig. 1(B (iv))]. These results support a link
between multiple treatments with hylan G-F 20 and the presence
of inﬂammatory cells as an immediate immune response against
big aggregates of particles. Additionally, the immunohistochemical
analysis of the synovial tissue further identiﬁed the speciﬁc types of
cells involved in the acute ﬂare of the case patient. The analysis
identiﬁed a predominant population of CD3/CD5-positive T
lymphocytes [Fig. 1(C (i)), CD3 positivity] with scattered CD20-
positive B-cells [Fig. 1(C (ii))]. Scattered mast cells positive for
CD117 [Fig. 1(C (iii))] and numerous macrophages positive for CD68
[Fig. 1(C (iv))] were also present. The predominant presence of
macrophages (34%) and T lymphocytes (29%) with only 2% B
lymphocytes and 1.5% mast cells in the inﬂammatory inﬁltrate,
while suggestive of an immune mechanism mediated by these
cells, is only partially similar to that identiﬁed in rheumatoid
arthritis (RA)-like inﬂammatory arthritis10, where B lymphocytes
generally presenting in signiﬁcant number play a major role.
During the arthroscopic debridement, synovial ﬂuid was
obtained for further studies of immune-driven acute joint inﬂam-
mation. In addition to our case patient, we utilized three repre-
sentative RA and three OA patients to address the comparison with
positive and negative controls. The patients, the majority of whom
were the same gender as our patient and of ages ranging from 40 to
78 years, signed an informed consent and the necessary synovial
samples were obtainedwith the approval of the Hospital for Special
Surgery (HSS) Institutional Review Board. The study focused further
on local activation of the complement pathway, speciﬁcally C5a and
C5b-9, which are well-described players in the development of
synovitis in immune arthritides. Previous reports have suggested
that C5a and C5b-9 concentrations are elevated in RA joints relative
to OA joints11e13 as well as the central role of C5b-9 in crystal-
induced arthropathies14. Enzyme-linked immunosorbent assays
(ELISAs) for markers of complement activation and cytokines were
performed. The concentrations of interleukin-1 beta (IL-1b), C5a
and C5b-9 in synovial ﬂuid were determined using commercially
available ELISAs (IL-1b and C5b-9: BD Biosciences, Franklin Lakes,
NJ; C5a: R&D Systems, Minneapolis, MN), according to the manu-
facturers’ instructions. Our experimental results demonstrate that
the concentrations of IL-1b in the case patient (210 pg/ml) were
nine times higher than in RA patients (25 pg/ml) and 100 times
higher than in OA patients (2 pg/ml) [Fig. 2(A (i))]. The complement
fragment C5a concentration was 9 ng/ml, closer to the average
concentration of 10 ng/ml in the synovial ﬂuids of the three RA
patients, but almost four times higher than the average concen-
tration of 2.5 ng/ml in the three OA patients [Fig. 2(A (ii))]. The
concentration of the C5b-9 complex was highest in our case patient
at 5500 ng/ml, compared to the average concentrations in synovial
ﬂuids of 4500 ng/ml in the RA patients and 800 ng/ml in the OA
patients [Fig. 2(A (iii))]. Therefore, we hypothesize that the local
immune proﬁle changed in the patient from a low inﬂammatory
response characteristic of OA to a highly inﬂammatory arthritis
pattern with a predominant synovial T lymphocytic inﬁltrate
[Fig. 1(C (i))], alongside a neutrophilic and eosinophilic inﬁltration
in the synovial exudate around hylan G-F 20 particles [Fig. 1(B (i)
and (ii))]. This immunological response is interpreted in a large part
to be secondary to the activation of the complement pathway, since
the lymphocytic inﬁltrate observed inOA is usually perivascular and
of mixed B and T cell pattern, with scattered presence of mast cells.
The numerous macrophagic component is considered secondary to
OA and also to the hylan deposits [Fig. 1(B (iv) and C (iv))].
Fig. 1. A. Inﬂammatory cells (macrophages) with hylan G-F 20. (i, ii) Mixed cell population isolated from ﬁbrinous exudate and synovial tissue showing macrophages containing
small vesicles with hylan G-F 20 at 50 (i) and 200 (ii) magniﬁcation. B. Histologic photomicrographs of synovial tissue of an OA patient treated with hylan G-F 20. (ieiv) Sections
of left knee synovium stained with H&E. Scale bars represent 200 um. (i) A particle of hylan G-F 20 in ﬁbrinous exudate is surrounded by a thick cuff of inﬂammatory cells (100
magniﬁcation); (ii) the inﬁltrate is composed of neutrophils and eosinophils (400 magniﬁcation); (iii) the inﬂammatory inﬁltrate is predominant in the ﬁbrinous exudate with
relative sparing of the synovial membrane (100 magniﬁcation); and (iv) an old particle of hylan G-F 20 in the synovium is associated with a palisading macrophagic reaction and
new acute inﬂammatory inﬁltrate (200 magniﬁcation). Hylan G-F 20 presence is indicated by the letter H and acute inﬂammatory inﬁltrate by the letter I; letter M demonstrates
the macrophagic reaction. C. Photomicrographs of immune cells in synovial tissue from hylan G-F 20-treated OA patient. (ieiv) The distribution of inﬂammatory cells is shown in
a representative area of the synovial membrane. (i) T lymphocytes, CD3; (ii) B lymphocytes, CD20; (iii) mast cells, CD117; and (iv) macrophages, CD68. All images were captured at
200 magniﬁcation. The presence of positive cells was counted by ImageJ as percentage vs total number of nuclei of cells counterstained with toluidine blue. We identiﬁed
numerous T lymphocytes and macrophages within the inﬂammatory areas surrounding hylan G-F 20 particles. D. Histologic photomicrographs of cancellous bone and marrow of an
OA patient treated with hylan G-F 20. (ieii) Sections of cancellous bone and marrow stained with H&E. (i) Particles of hylan G-F 20 in bone marrow surrounded by macrophagic
reaction and inﬂammatory cells (40magniﬁcation). Hylan G-F 20 presence is indicated by the letter H and trabecular bone by the letter T; (ii) expanded image of squared box in (i)
with inﬂammatory inﬁltrate composed of numerous lymphocytes and eosinophils on the left side and macrophages with a giant cell on the right side (400 magniﬁcation).
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well with the presence and extent of inﬂammatory synovitis in
OA and RA11. In the case patient, we observed diffuse presence of
stained C5b-9 deposits intermixed with inﬂammatory cells in the
ﬁbrinous exudate and vascular endothelial cells with a membra-
nous pattern [Fig. 2(B (iii) and (iv))]. RA patients showed a similar
distribution [Fig. 2(B (ii))], whereas in OA patients there were not
any deposits [Fig. 2(B (i))]. Three marker genes with major roles
in local joint inﬂammation, IL-1b, IL-6 and a neutrophil marker
myeloperoxidase (MPO), were also analyzed by quantitative real-
time polymerase chain reaction (RT-PCR) in synovial tissues of
the case patient alongside the three OA and three RA patients
[Fig. 2(C(i)e(iii))]. The presence of numerous neutrophils in
the inﬂamed knee joint may contribute greatly in our case
patient to local ﬂare, and the production of abundant cytokinessuch as IL-1b and IL-6 and speciﬁc enzymes such as MPO15. IL-1b
and IL-6 are major inﬂammatory cytokines expressed in syno-
vium in RA16, but at lower levels in OA patients17. In our patient
synovium, IL-1b mRNA was 34-fold higher compared to OA
patient samples and 15-fold higher than in synovium from RA
patients [Fig. 2(C (i))]. In addition, the IL-6 mRNA levels were
similar to those for IL-1b and 36-fold and 16-fold higher than
those in the OA and RA patients respectively [Fig. 2(C (ii))]. MPO
gene expression was ﬁve times higher in the patient injected
with hylan G-F 20 than in the RA and OA patients [Fig. 2(C (iii))];
however, the patients in the RA and OA groups demonstrated
little elevation. This might be a direct result of the high number
of neutrophils present in the synovium of the case patient and
a less severe OA phenotype because MPO is considered a possible
marker of early OA15.
Fig. 2. A. IL-1b, complement C5a and C5b-9 complexes present at high levels in synovial ﬂuid of the OA patient after multiple hylan G-F 20 injections compared to non-treated OA and
RA patients. Comparisons were done between non-treated OA (N¼ 3) and non-treated RA (N¼ 3) patients and OA patient treated with hylan G-F 20 (N¼ 1). (i) IL-1b concentration in
the case patient diagnosedwith OA and treatedwith hylanG-F 20 injections vs non-treated OA and RA patients. The hylan G-F 20-treated patient has complement (ii) C5a and (iii) C5b-
9 complexes that are present and at levels similar to those in an inﬂammatory joint with RA. The data are representative of three independent experiments performed in duplicate. B.
Photomicrographs of synovial tissue stained against C5b-9 (black arrow): (i) Negative endothelial cells in OA (non-treated patient); (ii) positive endothelial cells in RA (non-treated
patient); (iii) positive endothelial cells in the synovial membrane of the reported case; and (iv) ﬁbrinous exudate with positive staining in the inﬂammatory inﬁltrate of the reported
case. Scale bars are 200 um. C. IL-1b, IL-6 andMPO expression of mRNA isolated from synovial tissue of the OA patient after multiple hylan G-F 20 injections compared to non-treated
OA and RA patients. (i) Levels of IL-1b, (ii) IL-6, and (iii) MPO mRNA were analyzed by RT-PCR. Comparisons were done between non-treated OA (N¼ 3) and non-treated RA (N¼ 3)
patients and OA patient treated with hylan G-F 20 (N¼ 1). Gene expression levels are shown as fold-change relative to GAPDH. All experiments were performed in duplicate.
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proﬁle of the case patient. First, the reaction indicated similarities
with ﬂares in crystal-induced arthropathies associated with cell
surface cleavage of C5 and formation of the complement attack
complex (C5b-9)14 while the phagocytosis of hylan G-F 20 by
macrophages triggered the NLRP3 inﬂammasome activation with
release of inﬂammatory mediators and inﬂux of neutrophils in the
joint18. Second, an alternative hypothesis of previous sensitization5
via deposits of hylan G-F 20 is worthy of consideration. We have
recently observed a case of total knee replacement in a female
patient also affected by grade 4 OA. In addition of numerous
eosinophils and scattered neutrophils [Fig. 1(D (i) and (ii))],
deposits of hylan with palisading macrophages and giant cells and
scattered lymphocytes were equally present in the bone marrow
and synovium. However, to make conclusions about a comparable
process, more studies of the acute ﬂare reactions in similar patients
are necessary. Third, in this study we have presented similarities
with inﬂammatory arthropathies such as reactive arthritis and RA
illustrated by the presence of numerous T lymphocytes and
macrophages, complement activation, and release of speciﬁc pro-
inﬂammatory cytokines. Nevertheless, this association might not
be ideal when the cellular composition of the immune inﬁltrate,
almost virtual absence of CD20þ and CD38þ cells and the presence
of eosinophils, is carefully examined.While severe, the inﬂammatory knee changes were only
temporarily present. Beneﬁting from rehabilitation therapy, by 6
months, the knee functionality was fully recovered, and at 1 year,
the same performance level was observed as before the acute
reaction occurred.
In this study we cannot assess why the ﬂare did not occur in the
contralateral joint or at other times during the treatment regimen.
The severity of OA, the prolonged presence of the foreign substance
in the synoviumand the accumulationexceeding a certain threshold
may be contributing factors to a local sensitization in certain
susceptible individuals. Additional studies of the acuteﬂare reaction
in patients with multiple treatments of viscosupplementation are
warranted.
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